Age, years, mean ± SD
|
66 ± 10
|
66 ± 11
|
0.85
|
Male sex, n (%)
|
28 (58)
|
27 (68)
|
0.45
|
Duration of CAD, months, median (IQR)
|
24 (81)
|
32 (119)
|
0.39
|
History of myocardial infarction, n (%)
|
30 (63)
|
19 (48)
|
0.17
|
Number of myocardial infarctions, mean ± SD
|
0.8 ± 0.9
|
0.6 ± 0.8
|
0.28
|
NYHA class, mean ± SD
|
2.9 ± 0.7
|
2.6 ± 0.6
|
0.04
|
Number of coronary arteries with significant stenosis, mean ± SD
|
2.7 ± 0.6
|
2.6 ± 0.7
|
0.44
|
Acute coronary syndrome, n (%)
|
12 (25)
|
10 (25)
|
0.90
|
Left ventricular ejection fraction, mean ± SD
|
64 ± 12
|
65 ± 11
|
0.52
|
Previous heart surgery, n (%)
|
1 (2.1)
|
0 (0)
|
0.73
|
Positive family history of CAD,a
n (%)
|
33 (69)
|
31 (78)
|
0.41
|
C-reactive protein, mg/L, median (IQR)
|
4.9 (10.5)
|
2.1 (2.6)
|
<0.001
|
ESR, mm/h, median (IQR)
|
23 (28)
|
13 (17)
|
0.003
|
Troponin I, ng/ml, median (IQR)
|
0.06 (0.11)
|
0.01 (0.04)
|
0.01
|
Body mass index, kg/m2, mean ± SD
|
25 ± 4
|
26 ± 3
|
0.58
|
Hypertension, n (%)
|
28 (58)
|
20 (50)
|
0.46
|
Current smoker, n (%)
|
13 (27)
|
7 (18)
|
0.26
|
Previous smoking, n (%)
|
18 (38)
|
18 (45)
|
0.45
|
Diabetes mellitus, n (%)
|
6 (13)
|
5 (13)
|
0.87
|
Hypercholesterolemia, n (%)
|
40 (83)
|
36 (90)
|
0.45
|
Acetylsalicylic acid, n (%)
|
43 (90)
|
35 (88)
|
0.88
|
ACE inhibitors, n (%)
|
15 (31)
|
12 (30)
|
0.91
|
Statins, n (%)
|
37 (77)
|
32 (80)
|
0.70
|
Beta blockers, n (%)
|
36 (75)
|
31 (78)
|
0.71
|
Disease-modifying antirheumatic drugs,b
n (%)
|
16 (33)
|
0 (0)
|
<0.001
|
Systemic glucocorticosteroids, n (%)
|
19 (40)
|
0 (0)
|
<0.001
|
Nonsteroidal anti-inflammatory drugs, n (%)
|
6 (13)
|
0 (0)
|
0.018
|
Cyclooxygenase 2 selective inhibitors, n (%)
|
8 (17)
|
0 (0)
|
0.004
|
Duration of IRD, years, mean ± SD
|
17 ± 12
|
NA
|
NA
|
Patient’s global assessment of disease activity,c mean ± SD
|
3.1 ± 2.5
|
NA
|
NA
|
Physician’s global assessment of disease activity,c mean ± SD
|
1.4 ± 1.3
|
NA
|
NA
|